IFNAR Activator

Allura Red AC (Standard) is an analytical standard of Allura Red AC. This product is intended for research and analytical applications. Allura Red AC is a food colorant, appearing as a deep red water-soluble powder or granules, used in various applications such as beverages, syrups, candies, and cereals. Allura Red AC can statically quench the intrinsic fluorescence of HSA. Additionally, Allura Red AC is a 5-hydroxytryptamine (5-HT) pathway-associated pro-inflammatory agent, capable of exacerbating experimental colitis. Allura Red AC holds potential for research in inflammatory bowel disease (IBD), intestinal barrier function, and food additive safety.

Anti-CD160 Antibody (MAT 302) (CL1-R2) is a human monoclonal antibody targeting CD160. Anti-CD160 Antibody (MAT 302) blocks the CD160-HVEM protein interaction, inhibits FGF2-mediated renal tubular vascular growth, and induces endothelial cell apoptosis. Anti-CD160 Antibody (MAT 302) targets CD160 on neovascularization to exert anti-angiogenic and vascular normalization effects, trigger the production of IFN-γ, TNF and IL-6 by NK cells, and enhance glucose metabolism of NK cells through the AKT/mTOR/s6k signaling pathway. Anti-CD160 Antibody (MAT 302) reduces vascular density, normalizes remaining tumor blood vessels, and inhibits tumor growth in melanoma-bearing mice. Anti-CD160 Antibody (MAT 302) can be used in research related to neovascularization, proliferative diabetic retinopathy, and melanoma.

Peginterferon alfa-2a (Ro 25-8310/000) is a 40 kDa branched pegylated IFN alfa-2a with antiviral and immunomodulatory activities. Peginterferon alfa-2a binds to the Interferon Receptor on the surface of target cells, induces the formation of ISGF3, and promotes the expression of effector proteins such as interferon-stimulated genes (ISGs) and Mx proteins, thereby exerting sustained antiviral effects. Peginterferon alfa-2a is applicable to research on virus infections associated with chronic hepatitis C and chronic hepatitis B.

2',3'-cGAMP (Standard) is the analytical standard of 2',3'-cGAMP (HY-100564). This product is intended for research and analytical applications. 2',3'-cGAMP (2'-3'-cyclic GMP-AMP) is a endogenous cGAMP in mammalian cells. 2',3'-cGAMP binds to STING with a high affinity and is a potent inducer of interferon-β (IFNβ). 2',3'-cGAMP is produced in mammalian cells in response to DNA in the cytoplasm.

(S,S)-Formoterol ((+)-Formoterol) is the (S,S)-enantiomer of Formoterol (HY-B0010B). (S,S)-Formoterol is a β₂-adrenergic receptor (β₂-adrenergic receptor) ligand. (S,S)-Formoterol can induce mast cell mediator release, peribronchial and perivascular inflammatory cell infiltration, basal airway tone, IFN-γ production, and IL-4 production. (S,S)-Formoterol acts through the β₂-adrenergic receptor, altering its transduction pathways and modulating receptor structure and function. (S,S)-Formoterol can be used in the study of asthma.

MB-314 is a human IgG1 monoclonal antibody (mAb) targeting Lewis Y. MB-314 induces enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MB-314 increases the release of IFN-γ, TNF-α, MCP-1, and IL-6. MB-314 can be used in cancer research.

MSP-1 (20-39) is a peptide segment that can induce the production of IFN-γ. MSP-1 (20-39) has the potential to serve as a malaria vaccine. MSP-1 (20-39) can be used for research on malaria or immunology.

MG-1131 is a human monoclonal antibody (mAb) targeting TIGIT. MG-1131 activates NF-κB signaling in T cells and enhances NK-mediated tumor killing activity in a PVR-dependent manner. MG-1131 blocks TIGIT to increase IFN-γ secretion. MG-1131 can be used in anti-tumor immunity research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001).

PD-L1-IN-12 is an orally active and potent selenium-containing small-molecule PD-L1 inhibitor (K_D = 9.06 nM). PD-L1-IN-12 can mediate the internalization of PD-L1 and strongly block hPD-1 and hPD-L1 interaction (IC₅₀ = 5.2 nM). PD-L1-IN-12 can be used in colorectal cancer immunology research.

2'2'-cGAMP, a synthetic CDN, binds STING in the immune response, inducing IFN-β. 2'2'-cGAMP binds weaker binding to STING than 2'3'-cGAMP (HY-100564) but stronger than other CDNs.

STING agonist-50 is an orally active STING agonist with an IC₅₀ of 3.457 μM. STING agonist-50 activates the STING signaling pathway and promotes the phosphorylation of downstream TBK1 and IRF3. STING agonist-50 induces the expression of IFN-β, CXCL10 and IL-6. STING agonist-50 inhibits tumor growth in syngeneic mouse models. STING agonist-50 can be used for the research of colorectal cancer.

GSK2245035 maleate is a highly potent and selective intranasal Toll-Like receptor 7 (TLR7) agonist with preferential Type-1 interferon (IFN)-stimulating properties. GSK2245035 maleate has pEC₅₀s of 9.3 and 6.5 for IFNα and TFNα. GSK2245035 maleate effectively suppresses allergen-induced Th2 cytokine production in human peripheral blood cell cultures. GSK2245035 maleate is used for asthma.

ASP8374 is a human IgG4 monoclonal antibody (mAb) targeting TIGIT. ASP8374 increases IL-2 production in Jurkat cells and IFN-γ and TNF-α production in human PBMCs. ASP8374 can be used in advanced solid tumors research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003).

PD-1/PD-L1-IN-54 (Compound 6) is a moderately affinic PD-1/PD-L1 inhibitor (K_D: PD-1, 55.8 μM; PD-L1, 46.4 μM; IC₅₀: 88.6 μM). PD-1/PD-L1-IN-54 inhibits PD-1/PD-L1 interactions and shows anticancer activity by activating CD8⁺ T cells, upregulating PD-1 expression, and increasing secretion of IFN-γ and IL-2. PD-1/PD-L1-IN-54 inhibits cancer cell proliferation and promotes apoptosis. PD-1/PD-L1-IN-54 also regulates T cell immunity through the PI3K/Akt pathway correlated with PD-1/PD-L1.

S-palm P0(180-199) is an S-palmitoylated peptide derived from P0 protein. S-palm P0(180-199) induces IL-17+ cells, macrophage infiltration, and anti-P0 antibodies. S-palm P0(180-199) induces chronic inflammatory demyelinating polyneuropathy in rats via active immunization, manifesting as a relapsing-remitting disease driven by persistent T cells, macrophages, Th17 cells and related cytokines, and P0-specific IgG. S-palm P0(180-199) can be used in research related to chronic inflammatory demyelinating polyneuropathy.

mDF6002 is a IL-12R-Fc fusion protein. mDF6002 induces sustained IFNγ production. mDF6002 exerts tumor-suppressive effects in mouse models of colon cancer and melanoma. mDF6002 can be used for research on solid tumors such as colon cancer and melanoma.

MEDI-3622 is a human monoclonal antibody against ADAM17. MEDI-3622 blocks the ADAM17-mediated shedding of CD16A and CD62L on NK cells, and binds with high specificity to a surface loop unique to the metalloprotease catalytic domain of ADAM17. MEDI-3622 enhances IFNγ production by NK cells when they bind to antibody-coated tumor cells. MEDI-3622 can be used in the research of ovarian cancer, Burkitt lymphoma, head and neck cancer, and colorectal cancer.

PD-1/PD-L1-IN-65 is a PD-1/PD-L1 checkpoint inhibitor, with an EC₅₀ of 6.06 μM for blocking the PD-1/PD-L1 interaction and a K_d of 1.43 μM for PD-L1. PD-1/PD-L1-IN-65 upregulates pro-inflammatory cytokines IFN-γ, IL-1α, IL-1β and the cytolytic protein perforin, and reverses T cell exhaustion. PD-1/PD-L1-IN-65 enhances T cell-mediated cancer cell lysis. PD-1/PD-L1-IN-65 can be used in the research of breast cancer.

Fa-Au is a TrxR inhibitor. Fa-Au downregulates GPX4, induces oxidative stress, mitochondria-associated ferroptosis (ferroptosis) and immunogenic cell death. Fa-Au induces ROS production in hepatoma cells. Fa-Au remodels the tumor immune microenvironment via M1 macrophage polarization, dendritic cell maturation, CD8+ T cell activation and reduction of regulatory T cells. Fa-Au induces an anti-tumor immune feedback loop through the IFNγ/STAT1/SLC7A11 axis. Fa-Au inhibits tumor growth. Fa-Au is applicable to hepatocellular carcinoma-related research.

TLR7/8 agonist 14 is a TLR7 and TLR8 agonist with EC₅₀ values of 0.53 μM and 4.3 μM, respectively. TLR7/8 agonist 14 increases the secretion of the proinflammatory cytokines TNF-α, IL-1β, IL-8 and IFN-γ. TLR7/8 agonist 14 increases cytokine secretion and expression of CD86. LR7/8 agonist 14 can be used for research colorectal carcinoma.